Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
PMID: 38459910
Source: Inflamm Bowel Dis
Publication date:
2025-07-24
Year:
2024
Abstract
NULL